PDT Partners LLC Purchases 97,539 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

PDT Partners LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 385.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 122,842 shares of the company’s stock after acquiring an additional 97,539 shares during the quarter. PDT Partners LLC owned about 0.06% of Cellebrite DI worth $2,706,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. NewEdge Advisors LLC increased its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after purchasing an additional 3,352 shares in the last quarter. R Squared Ltd bought a new stake in Cellebrite DI in the 4th quarter valued at about $100,000. Polen Capital Management LLC acquired a new position in Cellebrite DI during the 4th quarter worth approximately $222,000. Victory Capital Management Inc. bought a new position in Cellebrite DI in the fourth quarter worth approximately $234,000. Finally, HighTower Advisors LLC acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $274,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CLBT has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital boosted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $20.10 on Wednesday. The company has a market cap of $4.81 billion, a P/E ratio of -14.46, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The firm has a 50-day moving average of $18.76 and a 200-day moving average of $20.15.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.